Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial

Erstveröffentlichung

2018

Metadata only
Search for full text

Wissenschaftlicher Artikel

Authors

Cramer, Paula

von Tresckow, Julia

Bahlo, Jasmin

Robrecht, Sandra

Langerbeins, Petra

et al.

Institutions

UKU. Klinik für Innere Medizin III

Published in

Lancet Oncology ; 19 (2018), 9. - S. 1215-1228. - ISSN 1470-2045. - eISSN 1474-5488

Link to publication

https://dx.doi.org/10.1016/S1470-2045(18)30414-5

Funding information

F Hoffmann-La Roche
AbbVie

Keywords

minimal residual disease; in-vitro; ii trial; rituximab; ibrutinib; cyclophosphamide; fludarabine; cll; chemoimmunotherapy; progression

Dewey Decimal Group

DDC 610 / Medicine & health

---

Metadata

Show full item record